This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAHA | |
|---|---|
| Name | MAHA |
| Field | Hematology |
MAHA is an acronym denoting a hematologic syndrome characterized by fragmentation of red blood cells with resultant anemia, thrombocytopenia, and microvascular complications. It intersects with a range of clinical entities including thrombotic microangiopathies, vasculitides, and obstetric disorders, and appears in contexts such as transplantation, sepsis, and pharmacologic toxicity. Historical descriptions and modern definitions link MAHA to diagnostic frameworks used in tertiary centers, forensic evaluations, and multicenter clinical trials.
The term arose in 20th-century hematologic literature and derives from composite nomenclature used in case series and consensus statements promulgated by specialist groups at institutions like Mayo Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, and European centers such as Hôpital Saint-Louis and Charité – Universitätsmedizin Berlin. Early usage parallels terminology adopted in reports by investigators associated with American Society of Hematology, European Hematology Association, and working groups convened after outbreaks and epidemics scrutinized by Centers for Disease Control and Prevention and World Health Organization. The acronym is comparable to nomenclature conventions seen in syndromes named in guidelines from National Institutes of Health and position papers from the British Society for Haematology.
Clinically, MAHA is defined within classification schemes used for entities like thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and secondary microangiopathies associated with systemic lupus erythematosus, scleroderma renal crisis, and malignancy-related microangiopathy. Subtyping appears in consensus documents produced by panels including representatives from International Society on Thrombosis and Haemostasis, European Renal Association – European Dialysis and Transplant Association, and specialty registries at Children's Hospital of Philadelphia. Distinctions parallel criteria applied in diagnostic algorithms from American College of Physicians and case definitions used in registries maintained by National Cancer Institute and transplant consortia like United Network for Organ Sharing.
Presentation often prompts consultation across services at centers such as Cleveland Clinic, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, and referral networks linked to Mount Sinai Hospital. Patients may present with pallor, jaundice, oliguria, neurologic deficits, and bleeding manifestations that lead to hematology, nephrology, and critical care evaluation by teams akin to those at Addenbrooke's Hospital or Toronto General Hospital. Diagnostic workup uses peripheral smear interpretation consistent with training from Royal College of Pathologists, biochemical panels endorsed by Clinical and Laboratory Standards Institute, and imaging protocols familiar to practitioners at John Radcliffe Hospital and Karolinska University Hospital. Laboratory confirmation relies on demonstration of schistocytes, elevated lactate dehydrogenase, and reduced haptoglobin as standardized in assays employed at reference labs like Mayo Clinic Laboratories.
Mechanistic models draw on research from investigators affiliated with Harvard Medical School, University of Oxford, Stanford University School of Medicine, and University of California, San Francisco. Pathways implicated include shear-mediated erythrocyte fragmentation in microvascular beds seen in association with aortic stenosis, endothelial injury mediated by complement activation as characterized in studies from Institut Pasteur and Karolinska Institutet, and platelet-rich thrombi formation mechanisms elucidated in cohorts at University College London Heart and Lung Institute. Molecular players explored in translational studies include von Willebrand factor multimers investigated at Beth Israel Deaconess Medical Center and complement factors studied in trials coordinated by Imperial College London.
Management strategies mirror protocols developed at centers such as Massachusetts General Hospital, Royal Melbourne Hospital, and multicenter trial networks including National Institutes of Health Clinical Center and cooperative groups like European LeukemiaNet. Therapeutic interventions include plasma exchange regimens standardized in guidelines from American Society for Apheresis, complement inhibitors evaluated in trials at Mayo Clinic, immunosuppression protocols used in case series from Hospital Universitario La Paz, and organ support modalities delivered in intensive care units modeled after Johns Hopkins Hospital and St Thomas' Hospital. Anticoagulation, transfusion, and renal replacement approaches follow algorithms promulgated by societies such as Society of Critical Care Medicine.
Epidemiologic patterns have been described in cohort studies from national databases like those maintained by Centers for Medicare & Medicaid Services, population registries coordinated through Swedish National Board of Health and Welfare, and surveillance projects led by Public Health England. Incidence varies by underlying cause, with higher rates reported in settings associated with Shiga toxin-producing Escherichia coli outbreaks investigated by Centers for Disease Control and Prevention and in postpartum cohorts studied at King's College Hospital. Prognosis depends on etiology and treatment timeliness, with outcome analyses published by groups at Vanderbilt University Medical Center and Hospital Clinic Barcelona reporting mortality, renal recovery, and neurologic sequelae metrics.
Historical case reports and series came from investigators at institutions such as Guy's Hospital, Peter Bent Brigham Hospital, and European centers including Hôpital Necker–Enfants Malades, with landmark descriptions appearing in journals associated with Royal Society of Medicine and editorial offices at The Lancet and The New England Journal of Medicine. Notable outbreaks and legal–forensic cases involving microangiopathic hemolysis were examined in inquiries connected to BSE crisis reviews and transplant-related investigations at United Network for Organ Sharing. High-profile case series and randomized trials cited experiences from University of Pennsylvania Health System and multicenter collaborations coordinated by ClinicalTrials.gov-registered networks.